Haem arginate - Orphan Europe

Drug Profile

Haem arginate - Orphan Europe

Alternative Names: Hemin - Orphan Europe; Normosang

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Orphan Europe
  • Developer CMIC; Orphan Europe
  • Class Antibacterials; Antineoplastics; Haemes
  • Mechanism of Action Enzyme replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute intermittent porphyria
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute intermittent porphyria

Most Recent Events

  • 05 Jul 2012 Haem arginate licensed to Medunik in Canada
  • 07 Nov 2011 Registered for Acute intermittent porphyria in Russia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top